MedTrace Logo

Effect of OC000459 on Eosinophilic Airway Inflammation in Severe Asthma

NCT02560610 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2019-08-29

No results posted yet for this study

Summary

The aim is to study the effect of OC000459 on eosinophilic airway inflammation and asthma control in subjects with severe, refractory eosinophilic asthma.

Conditions

  • Severe Eosinophilic Asthma

Interventions

DRUG

OC000459

DRUG

Placebo

Sponsors & Collaborators

  • Atopix Therapeutics, Ltd.

    collaborator INDUSTRY

  • Chiesi Farmaceutici S.p.A.

    lead INDUSTRY

Principal Investigators

  • Ian Pavord, Professor · University of Oxford

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2018-08-02
Completion
2018-08-02

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02560610 on ClinicalTrials.gov